Anzeige
Mehr »
Login
Freitag, 14.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Das Vatertagsgeschenk für jeden Spekulanten?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 900964 ISIN: US64125C1099 Ticker-Symbol: NB3 
Tradegate
13.05.21
17:23 Uhr
76,26 Euro
-0,02
-0,03 %
1-Jahres-Chart
NEUROCRINE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
NEUROCRINE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
75,3276,8613.05.
75,1875,7813.05.

Aktuelle News zur NEUROCRINE BIOSCIENCES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.05.Neurocrine upgraded at Barclays despite Q1 earnings miss8
NEUROCRINE BIOSCIENCES Aktie jetzt für 0€ handeln
06.05.Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript4
06.05.Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation4
05.05.Neurocrine Biosciences Inc Q1 adjusted earnings Miss Estimates203WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) reported earnings for first quarter that dropped from the same period last year.The company's bottom line came in at $32.1 million, or...
► Artikel lesen
29.04.Lagging rival Neurocrine, Teva preps ad campaign in tardive dyskinesia28
19.04.Neurocrine Biosciences appoints Johanna Mercier to board2
16.04.NEUROCRINE BIOSCIENCES INC - 8-K, Current Report5
25.03.Why Neurocrine Biosciences Stock Jumped Today25
25.03.Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600209NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY)...
► Artikel lesen
24.03.Neurocrine Biosciences, O-I Glass jump on S&P index moves16
02.03.Neurocrine Biosciences' INTERACT Study Fails; Worse For Sentiment Than Value13
02.03.Neurocrine shares fall after mid-stage schizophrenia study results5
02.03.A spotlight schizophrenia drug in Neurocrine's $2B Takeda deal flunks its first major test. But it's not giving up yet17
02.03.Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity12
02.03.Neurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT Study305TOKYO (dpa-AFX) - Neurocrine Biosciences (NBIX) said the investigational drug luvadaxistat did not meet primary endpoint in the phase II INTERACT study in adults with negative symptoms of...
► Artikel lesen
17.02.Neurocrine pandemic play? Leverage marketing to launch Ongentys and keep Ingrezza steady8
09.02.Neurocrine Biosciences Upping Marketing Spend To Support Its Platform3
05.02.Neurocrine's revenue miss: Baird expects a rebound in 20216
05.02.More info. on Neurocrine Biosciences Q4 earnings3
05.02.NEUROCRINE BIOSCIENCES - Biotech-Aktie hat sich wieder gefangen18
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1